Trial · NCT01025284
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Part A: Percentage of Participants Achieving an Overall Response (Overall Response Rate) | Part A | 2.6 | 90% Confidence Interval 0.1 to 11.9 | percentage of participants | |
| Part B: Percentage of Participants Achieving a Best Response (Clinical Benefit Rate) | Part B | 26.9 | 90% Confidence Interval 13.4 to 44.7 | percentage of participants | |
| Part A: Progression-Free Survival | Part A | 5.3 | 90% Confidence Interval 5.1 to 5.7 | weeks | |
| Part B: Progression-Free Survival | Part B | 6.1 | 90% Confidence Interval 5.6 to 7.4 | weeks | |
| Part A: Percentage of Participants Achieving a Best Response (Clinical Benefit Rate) | Part A | 23.7 | 90% Confidence Interval 12.9 to 37.7 | percentage of participants | |
| Part B: Percentage of Participants Achieving an Overall Response (Overall Response Rate) | Part B | 0 | 90% Confidence Interval NA to NA | percentage of participants | |
| Part A: Pharmacokinetics - Maximum Observed Plasma Concentration (Cmax) of LY2523355 and Its Metabolite (LSN2546307) | Part A | LY2523355 Day 1 | 146 | Geometric Coefficient of Variation 69.5 | nanograms/milliliter (ng/mL) |
| Part A: Pharmacokinetics - Maximum Observed Plasma Concentration (Cmax) of LY2523355 and Its Metabolite (LSN2546307) | Part A | LY2523355 Day 5 | 157 | Geometric Coefficient of Variation 91.4 | nanograms/milliliter (ng/mL) |
| Part A: Pharmacokinetics - Maximum Observed Plasma Concentration (Cmax) of LY2523355 and Its Metabolite (LSN2546307) | Part A | LY2523355 Day 9 | 100 | Geometric Coefficient of Variation 420 | nanograms/milliliter (ng/mL) |
| Part A: Pharmacokinetics - Maximum Observed Plasma Concentration (Cmax) of LY2523355 and Its Metabolite (LSN2546307) | Part A | Metabolite Day 1 | 7.17 | Geometric Coefficient of Variation 55.4 | nanograms/milliliter (ng/mL) |
| Part A: Pharmacokinetics - Maximum Observed Plasma Concentration (Cmax) of LY2523355 and Its Metabolite (LSN2546307) | Part A | Metabolite Day 5 | 6.29 | Geometric Coefficient of Variation 50.8 | nanograms/milliliter (ng/mL) |
| Part A: Pharmacokinetics - Maximum Observed Plasma Concentration (Cmax) of LY2523355 and Its Metabolite (LSN2546307) | Part A | Metabolite Day 9 | 6.11 | Geometric Coefficient of Variation 129 | nanograms/milliliter (ng/mL) |
| Part B: Pharmacokinetics - Maximum Observed Plasma Concentration (Cmax) of LY2523355 | Part B - 5 mg/m²/Day | 128 | Geometric Coefficient of Variation 82 | nanograms/milliliter (ng/mL) | |
| Part B: Pharmacokinetics - Maximum Observed Plasma Concentration (Cmax) of LY2523355 | Part B - 6 mg/m²/Day | 258 | Geometric Coefficient of Variation 32 | nanograms/milliliter (ng/mL) | |
| Part B: Pharmacokinetics - Area Under the Plasma Concentration Versus Time Curve of LY2523355 From Time Zero to Infinity [AUC(0-∞)] | Part B - 5 mg/m²/Day | 639 | Geometric Coefficient of Variation 41 | nanograms*hour/milliliter (ng*h/mL) | |
| Part B: Pharmacokinetics - Area Under the Plasma Concentration Versus Time Curve of LY2523355 From Time Zero to Infinity [AUC(0-∞)] | Part B - 6 mg/m²/Day | 1220 | Geometric Coefficient of Variation 38 | nanograms*hour/milliliter (ng*h/mL) | |
| Total Lung Cancer Symptom Scale (LCSS) and Average Symptom Burden Index (ASBI) | Part B | Total LCSS at Baseline | 28.24 | Standard Deviation 15.2 | units on a scale |
| Total Lung Cancer Symptom Scale (LCSS) and Average Symptom Burden Index (ASBI) | Part B | Total LCSS at Follow-up | 42.61 | Standard Deviation 14.5 | units on a scale |
| Total Lung Cancer Symptom Scale (LCSS) and Average Symptom Burden Index (ASBI) | Part B | ASBI at Baseline | 26.76 | Standard Deviation 14.1 | units on a scale |
| Total Lung Cancer Symptom Scale (LCSS) and Average Symptom Burden Index (ASBI) | Part B | ASBI at Follow-up | 36.41 | Standard Deviation 11.1 | units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01025284/results